Summary
Abbott Laboratories filed its 2012 10-K report on February 14, 2013, detailing its business segments and financial performance. A significant event highlighted is the separation of its research-based pharmaceuticals business into a new independent company, AbbVie Inc., effective January 1, 2013. This separation reshapes Abbott's operational focus, with post-separation international sales expected to constitute a larger percentage of total revenue. The report outlines Abbott's diverse healthcare product portfolio, spanning Proprietary Pharmaceutical Products (largely spun off to AbbVie), Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The company emphasizes its commitment to research and development, investing billions annually to drive innovation across its segments. Regulatory compliance and managing healthcare cost containment efforts are noted as ongoing challenges. Financially, Abbott reported strong net sales and earnings for 2012. The company highlights the robust growth of its key product, HUMIRA®, and strategic acquisitions like Solvay Pharmaceuticals and Piramal Healthcare's Healthcare Solutions business, which expanded its global presence, particularly in emerging markets. Despite facing some challenges, including pricing pressures in Europe and legal settlements, Abbott maintained a solid financial position.
Financial Highlights
55 data points| Revenue | $19.05B |
| Cost of Revenue | $8.90B |
| Gross Profit | $10.15B |
| SG&A Expenses | $6.74B |
| Operating Expenses | $17.69B |
| Operating Income | $1.36B |
| Interest Expense | $320.00M |
| Net Income | $5.96B |
| EPS (Basic) | $3.76 |
| EPS (Diluted) | $3.72 |
| Shares Outstanding (Basic) | 1.57B |
| Shares Outstanding (Diluted) | 1.59B |
Key Highlights
- 1Significant business transformation through the separation of its research-based pharmaceutical business into AbbVie Inc., effective January 1, 2013.
- 2Abbott's business segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products, post-AbbVie separation.
- 3Strong performance in 2012 with continued growth in key products like HUMIRA®.
- 4Investment in R&D remained substantial, totaling $4.3 billion in 2012 to support pipeline development across segments.
- 5Strategic acquisitions, including Solvay Pharmaceuticals and Piramal Healthcare's Healthcare Solutions business, expanded Abbott's global footprint and product offerings.
- 6The company is navigating a complex regulatory environment and ongoing healthcare cost containment efforts globally.
- 7Abbott maintains a strong financial position, with significant cash flow from operations and a stable debt rating.